# Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C

> **NCT00421434** · PHASE2,PHASE3 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 121 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Nitazoxanide
- **BIOLOGICAL:** Peginterferon alfa-2a
- **BIOLOGICAL:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00421434
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2008-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421434, "Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00421434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*